Skip to content
← Full study record

NCT01371656 · FLOW

Participant flow

Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation · Source last updated 2020-12-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients receive levofloxacin PO or IV over 60-90 minutes once or twice daily beginning on day 3 during 2 consecutive courses of chemotherapy or beginning on day -2 during HSCT and continuing until blood counts recover. levofloxacin: Given PO or IV
    id
    FG000
    title
    Arm I (Levofloxacin)
  2. description
    Patients receive established standard of care and receive chemotherapy or HSCT as patients in Arm I.
    id
    FG001
    title
    Arm II (Standard of Care)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        7
      2. group Id
        FG001
        num Subjects
        4
      type
      Death
    2. reasons
      1. group Id
        FG000
        num Subjects
        46
      2. group Id
        FG001
        num Subjects
        7
      type
      Physician Decision
    3. reasons
      1. group Id
        FG000
        num Subjects
        7
      2. group Id
        FG001
        num Subjects
        0
      type
      Withdrawal by Subject
    4. reasons
      1. group Id
        FG000
        num Subjects
        4
      2. group Id
        FG001
        num Subjects
        3
      type
      Ineligible
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        314
      2. group Id
        FG001
        num Subjects
        310
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        250
      2. group Id
        FG001
        num Subjects
        296
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        64
      2. group Id
        FG001
        num Subjects
        14
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Patients receive levofloxacin PO or IV over 60-90 minutes once or twice daily beginning on day 3 during 2 consecutive courses of chemotherapy or beginning on day -2 during HSCT and continuing until blood counts recover. levofloxacin: Given PO or IV
    id
    FG000
    title
    Arm I (Levofloxacin)
  2. description
    Patients receive established standard of care and receive chemotherapy or HSCT as patients in Arm I.
    id
    FG001
    title
    Arm II (Standard of Care)
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        7
      2. group Id
        FG001
        num Subjects
        4
      type
      Death
    2. reasons
      1. group Id
        FG000
        num Subjects
        46
      2. group Id
        FG001
        num Subjects
        7
      type
      Physician Decision
    3. reasons
      1. group Id
        FG000
        num Subjects
        7
      2. group Id
        FG001
        num Subjects
        0
      type
      Withdrawal by Subject
    4. reasons
      1. group Id
        FG000
        num Subjects
        4
      2. group Id
        FG001
        num Subjects
        3
      type
      Ineligible
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        314
      2. group Id
        FG001
        num Subjects
        310
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        250
      2. group Id
        FG001
        num Subjects
        296
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        64
      2. group Id
        FG001
        num Subjects
        14
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice